<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ERYGEL- erythromycinÂ gelÂ </strong><br>Prestium Pharma, Inc.<br></p></div>
<h1><span class="Bold">Prestium Pharma, Inc. ERYGELÂ® (Erythromycin) Topical Gel USP, 2%</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2f8dc96b-0ed2-4bd6-8566-01490413a4dc"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">For Dermatologic Use Only â€“ Not for Ophthalmic Use</span></p>
<p><span class="Bold">Rx Only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_1a8851ca-552e-44f4-bf89-94987c7dcfe8"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">ERYGELÂ® Topical Gel USP, 2% contains erythromycin (3R*, 4S*, 5S*, 6R*, 7R*, 9R*, 11R*, 12R*, 13S*, 14R*)-4-[(2,6-Dideoxy-3-<span class="Italics">C</span>-methyl-3-<span class="Italics">O</span>-methyl-Î±-L-<span class="Italics">ribo</span>-hexopyranosyl)oxy]-14-ethyl-7, 12, 13-trihydroxy-3, 5, 7, 9, 11, 13-hexamethyl-6-[[3, 4, 6,-trideoxy-3-(dimethylamino)-Î²-D-<span class="Italics">xylo</span>-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione), for topical dermatological use. Erythromycin is a macrolide antibiotic produced from a <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of <span class="Italics">Saccaropolyspora</span><span class="Italics"></span><span class="Italics">erythraea</span> (formerly <span class="Italics">Streptomyces </span><span class="Italics">erythreus</span>). It is a base and readily forms salts with acids.</p>
<p>Chemically, erythromycin is C<span class="Sub">37</span>H<span class="Sub">67</span>NO<span class="Sub">13</span>. It has the following structural formula: </p>
<div class="Figure">
<a name="id-1745409095"></a><img alt="EryGel Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=26eb3e52-e857-4ab6-841e-fd47a838e4f4&amp;name=dd35ad79-e738-44b8-857e-c6d7d1dedcc0-01.jpg">
</div>
<p>Erythromycin has a molecular weight of 733.94. It is a white or slightly yellow, odorless or practically odorless, bitter crystalline powder. Erythromycin is very soluble in very polar organic solvents such as alcohols, acetone, chloroform, acetonitrile and ethyl acetate. It is moderately soluble in less polar solvents such as ether, dichloroethylene and amyl acetate. It is slightly soluble in nonpolar solvents such as hexane. It is very poorly soluble in water.</p>
<p>Each gram of ERYGELÂ® Topical Gel USP, 2% contains 20 mg of erythromycin USP in a vehicle consisting of dehydrated alcohol and hydroxypropyl cellulose.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_f8822256-0156-44dd-8ce9-3f39a6924d49"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">The exact mechanism by which erythromycin reduces lesions of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> is not fully known; however, the effect appears to be due in part to the antibacterial activity of the drug.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="ID_8cbf3fc1-94af-43b9-94c9-666fc4134186"></a><a name="section-4"></a><p></p>
<h1>MICROBIOLOGY</h1>
<p class="First">Erythromycin acts by inhibition of protein synthesis in susceptible organisms by reversibly binding to 50S ribosomal subunits, thereby inhibiting translocation of aminoacyl transfer-RNA and inhibiting polypeptide synthesis. Antagonism has been demonstrated <span class="Italics">in vitro </span>between erythromycin, lincomycin, chloramphenicol, and clindamycin.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_2e58215c-8727-4495-8211-fb4c1501f814"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">ERYGELÂ® Topical Gel USP, 2% is indicated for the topical treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_3ff42388-0907-4dd4-ba7b-5965c1581f0c"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">ERYGELÂ® Topical Gel USP, 2% is contraindicated in those individuals who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of its components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="ID_8dd560e4-c78e-4642-bc06-2372a15cfe3e"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> has been reported with nearly all antibacterial agents, including erythromycin, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> subsequent to the administration of antibacterial agents.</span></p>
<p>Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by <span class="Italics">Clostridium </span><span class="Italics">difficile</span><span class="Italics"></span>is one primary cause of â€œantibiotic-associated colitisâ€?. After the diagnosis of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> has been established, therapeutic measures should be initiated. Mild cases of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation and treatment with an antibacterial drug clinically effective against <span class="Italics">C. </span><span class="Italics">difficile</span> <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ID_9a1fdc74-f63c-49ed-9621-809528b5241f"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="ID_10751140-5661-4492-b5c7-0a356e92b71f"></a><a name="section-8.1"></a><p></p>
<h2>General - </h2>
<p class="First">For topical use only; not for ophthalmic use. Concomitant topical <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> therapy should be used with caution because a possible cumulative irritancy effect may occur, especially with the use of <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span>, desquamating or abrasive agents.</p>
<p>Avoid contact with eyes and all mucous membranes.</p>
<p>The use of antibiotic agents may be associated with the overgrowth of antibiotic-resistant organisms. If this occurs, discontinue use and take appropriate measures.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_e9590a5f-4f68-4939-a7b4-41e86c4089ca"></a><a name="section-8.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients using ERYGELÂ® Topical Gel USP, 2% should receive the following information and instructions:</p>
<dl>
<dt>1.</dt>
<dd>This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes, nose, mouth, and all mucous membranes.</dd>
<dt>2.</dt>
<dd>This medication should not be used for any disorder other than that for which it was prescribed.</dd>
<dt>3.</dt>
<dd>Patients should not use any other topical <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> medication unless otherwise directed by their physician.</dd>
<dt>4.</dt>
<dd>Patients should report to their physician any signs of local adverse reactions.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_1e9f1c8c-7517-4bf5-8ee0-2d47350ca98a"></a><a name="section-8.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility -</h2>
<p class="First">No animal studies have been performed to evaluate carcinogenic and mutagenic potential, or effects on fertility of topical erythromycin. However, long-term (2-year) oral studies in rats with erythromycin ethylsuccinate and erythromycin base did not provide evidence of tumorigenicity. There was no apparent effect on male or female fertility in rats fed erythromycin (base) at levels up to 0.25% of diet.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_3d2332d4-83b3-4a0f-be1d-bfc87e75c2b7"></a><a name="section-8.4"></a><p></p>
<h2>Pregnancy:</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="ID_3fca1388-d4ef-4f26-abfe-aac9e847d000"></a><a name="section-8.4.1"></a><p></p>
<h3><span class="Italics">Teratogenic Effects:</span></h3>
<div class="Section">
<a name="ID_693d38dd-1eee-4bc5-8438-eb36a03d5acb"></a><a name="section-8.4.1.1"></a><p></p>
<h4><span class="Bold"><span class="Italics">Pregnancy Category B - </span></span></h4>
<p class="First">There was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> or any other adverse effect on reproduction in female rats fed erythromycin base (up to 0.25% of diet) prior to and during mating, during gestation and through weaning of two successive litters. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed. Erythromycin has been reported to cross the placental barrier in humans, but fetal plasma levels are generally low.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_9764625b-b561-4867-9b89-bdff5d2b008d"></a><a name="section-8.5"></a><p></p>
<h2>Nursing Women - </h2>
<p class="First">It is not known whether erythromycin is excreted in human milk after topical application. However, erythromycin is excreted in human milk following oral and parenteral erythromycin administration. Therefore, caution should be exercised when erythromycin is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_a7f8cb0e-bd8b-4cba-ac90-fa382ce5fdbc"></a><a name="section-8.6"></a><p></p>
<h2>Pediatric Use - </h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5e39dd7c-f773-4786-9b9e-afb43cdf1d39"></a><a name="section-9"></a><p></p>
<h1>KEEP OUT OF REACH OF CHILDREN.</h1>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_da776d36-3cb3-482b-9058-9fed3fe98fc1"></a><a name="section-10"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">In controlled clinical trials, the incidence of burning associated with erythromycin topical gel USP, 2% was approximately 25%. The following additional local adverse reactions have been reported occasionally: <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span>, dryness, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, and oiliness. Irritation of the eyes and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> of the skin have also been reported with the topical use of erythromycin. A generalized urticarial reaction, possibly related to the use of erythromycin, which required systemic steroid therapy has been reported.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_4c5feef5-a916-4608-9c29-cbe1a21a5b7d"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">ERYGELÂ® Topical Gel USP, 2% should be applied sparingly as a thin film to affected area(s) once or twice a day after the skin is thoroughly cleansed and patted dry. If there has been no improvement after 6 to 8 weeks, or if the condition becomes worse, treatment should be discontinued, and the physician should be reconsulted. Spread the medication lightly rather than rubbing it in. There are no data directly comparing the safety and efficacy of b.i.d. versus q.d. dosing.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_951340b6-9fd2-4cd3-bd8c-809751e3f20c"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">ERYGELÂ® (Erythromycin) Topical Gel USP, 2% is available as follows:</p>
<p>   30 g sealed metal tube (NDC 40076-<span class="Bold">315</span>-94)</p>
<p>   60 g sealed metal tube (NDC 40076-<span class="Bold">315</span>-96)</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="ID_522f29ef-0a6d-4724-9827-05b82c95031e"></a><a name="section-13"></a><p></p>
<h1>STORAGE</h1>
<p class="First"><span class="Bold">Note - FLAMMABLE.</span><span class="Bold"> Keep away from heat and flame. </span>Store and dispense in original container. Keep tube tightly closed. Store at 20-25Â°C (68-77Â°F) [see USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3d0d6158-9bfa-4671-afc1-d7ef6c8db078"></a><a name="section-14"></a><p></p>
<p class="First">Prestium Pharma</p>
<p>Manufactured for Prestium Pharma, Inc.</p>
<p>Newtown, PA 18940</p>
<p>Manufactured by Perrigo </p>
<p>Yerham 80500, Israel</p>
<p>Made in Israel   Rev 08/13</p>
<p>:6J400 ZH J1</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_3ba7046c-1160-4473-9a29-5b38c10a87f0"></a><a name="section-15"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL - Carton</h1>
<p class="First">Net Wt 30 g</p>
<p>Rx only</p>
<p>ERYGELÂ®</p>
<p>(Erythromycin) Topical Gel USP, 2%</p>
<p>For Dermatologic Use Only</p>
<p>Not for Ophthalmic Use</p>
<div class="Figure">
<a name="id79720907"></a><img alt="Erygel Carton Image 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=26eb3e52-e857-4ab6-841e-fd47a838e4f4&amp;name=dd35ad79-e738-44b8-857e-c6d7d1dedcc0-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_36b10f8b-7f34-457a-946c-6e79e2c134e8"></a><a name="section-16"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL - Tube</h1>
<p class="First">Net Wt 30 g</p>
<p>ERYGELÂ® </p>
<p>(Erythromycin) Topical Gel USP, 2%</p>
<p>For Dermatologic Use Only</p>
<p>Not for Ophthalmic Use</p>
<p>Rx only</p>
<div class="Figure">
<a name="id-42441858"></a><img alt="Erygel Tube" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=26eb3e52-e857-4ab6-841e-fd47a838e4f4&amp;name=dd35ad79-e738-44b8-857e-c6d7d1dedcc0-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ERYGELÂ 		
					</strong><br><span class="contentTableReg">erythromycin gel</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:40076-315</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ERYTHROMYCIN</strong> (ERYTHROMYCIN) </td>
<td class="formItem">ERYTHROMYCIN</td>
<td class="formItem">20Â mg Â inÂ 1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (slighlty yellow, practically odorless) </td>
<td class="formLabel">Score</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:40076-315-30</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">30 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:40076-315-60</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">60 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA063211</td>
<td class="formItem">01/27/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Prestium Pharma, Inc.
							(078304674)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 1/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>dd35ad79-e738-44b8-857e-c6d7d1dedcc0</div>
<div>Set id: 26eb3e52-e857-4ab6-841e-fd47a838e4f4</div>
<div>Version: 2</div>
<div>Effective Time: 20140127</div>
</div>
</div>Â <div class="DistributorName">Prestium Pharma, Inc.</div></p>
</body></html>
